Veracyte, Inc.
VCYT
$24.32
$0.682.88%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 463.39M | 445.76M | 425.33M | 399.58M | 375.47M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 463.39M | 445.76M | 425.33M | 399.58M | 375.47M |
| Cost of Revenue | 136.99M | 136.07M | 128.38M | 122.05M | 118.14M |
| Gross Profit | 326.41M | 309.70M | 296.96M | 277.53M | 257.34M |
| SG&A Expenses | 207.44M | 204.31M | 202.44M | 194.76M | 190.41M |
| Depreciation & Amortization | 14.40M | 14.85M | 15.80M | 17.34M | 18.89M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 429.88M | 424.52M | 415.30M | 398.59M | 387.94M |
| Operating Income | 33.51M | 21.24M | 10.04M | 994.00K | -12.46M |
| Income Before Tax | 35.08M | 25.74M | -8.17M | -54.79M | -70.43M |
| Income Tax Expenses | 2.03M | 1.61M | 1.10M | -750.00K | -2.25M |
| Earnings from Continuing Operations | 33.05 | 24.14 | -9.27 | -54.04 | -68.18 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 33.05M | 24.14M | -9.27M | -54.04M | -68.18M |
| EBIT | 33.51M | 21.24M | 10.04M | 994.00K | -12.46M |
| EBITDA | 56.74M | 44.70M | 33.58M | 25.98M | 13.65M |
| EPS Basic | 0.43 | 0.31 | -0.14 | -0.74 | -0.93 |
| Normalized Basic EPS | 0.36 | 0.25 | 0.21 | 0.11 | -0.03 |
| EPS Diluted | 0.41 | 0.30 | -0.15 | -0.75 | -0.94 |
| Normalized Diluted EPS | 0.36 | 0.25 | 0.20 | 0.11 | -0.03 |
| Average Basic Shares Outstanding | 309.19M | 305.92M | 301.42M | 297.21M | 293.15M |
| Average Diluted Shares Outstanding | 315.59M | 310.29M | 303.49M | 297.83M | 293.15M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |